# CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

> **NCT03934840** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 22 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Carboplatin
- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03934840
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-10
- **Primary completion:** 2023-06-19
- **Final completion:** 2025-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03934840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03934840, "CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03934840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*